GRN1005

DRUG2 trials

Sponsors

Angiochem Inc

Conditions

Brain MetastasesBreast CancerNon-small Cell Lung Cancer (NSCLC) With Brain Metastases

Phase 2

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

CompletedNCT01480583

Angiochem IncBrain Metastases, Breast Cancer

Start: 2011-10-31End: 2015-10-31Updated: 2016-07-13

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

TerminatedNCT01497665

Angiochem IncNon-small Cell Lung Cancer (NSCLC) With Brain Metastases

Start: 2011-11-30End: 2013-02-28Updated: 2019-01-22

Related Papers

ANG1005 for brain metastases from breast cancer: 18F-FLT-PET and MRI as complementary approaches to response assessment.

Journal of Clinical Oncology2015-05-202 citations